Validating registry data on statins prescriptions by blood measurements

Anders H Riis, Rune Erichsen, Eva B Ostenfeld, Carsten S Højskov, Ole Thorlacius-Ussing, Mogens Tornby Stender, Timothy L Lash, Holger Jon Møller

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

Purpose: To validate prescription registry data as a measurement of adherence to statins through a direct method using assays for selected statins in serial blood samples collected from two prospective cohorts of Danish colorectal cancer patients. Methods: We linked information on statin prescriptions from the Aarhus University Prescription Database with the cancer cohorts from Aalborg University Hospital. For statin-prescribed patients, we calculated a prescription window covering the anticipated duration of the prescription. For each statin-prescribed patient with at least one blood sample in a prescription window, we selected without replacement a never–statin-prescribed patient matched on sex, age, and calendar year of surgery. Each of the selected blood samples were analyzed using assays to detect statins. We calculated the positive and negative predictive value of the prescription registry reporting using the assay result as the gold standard. Results: We identified 73 ever–statin-prescribed patients with a total of 253 blood samples and 74 blood samples among never–statin-prescribed patients. The positive predictive value for prescribed patients, with presence of statins in at least one blood sample as the gold standard, was 93% (95% CI, 86%-97%) and the negative predictive value was 93% (95% CI, 86%-97%). Stratified results did not reveal substantial differences in predictive values. Fifty-two (71%) of the statin-prescribed patients had statins in every blood sample, suggesting continuous adherence. Conclusion: This study showed a high adherence with treatment with statins among colorectal cancer patients.

OriginalsprogEngelsk
TidsskriftPharmacoepidemiology and Drug Safety
Vol/bind28
Udgave nummer5
Sider (fra-til)609-615
Antal sider7
ISSN1053-8569
DOI
StatusUdgivet - maj 2019

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Prescriptions
Registries
Colorectal Neoplasms
Databases

Citer dette

Riis, Anders H ; Erichsen, Rune ; Ostenfeld, Eva B ; Højskov, Carsten S ; Thorlacius-Ussing, Ole ; Stender, Mogens Tornby ; Lash, Timothy L ; Møller, Holger Jon. / Validating registry data on statins prescriptions by blood measurements. I: Pharmacoepidemiology and Drug Safety. 2019 ; Bind 28, Nr. 5. s. 609-615.
@article{1f3248e5d4934f02a4f7dbba488d2c7a,
title = "Validating registry data on statins prescriptions by blood measurements",
abstract = "Purpose: To validate prescription registry data as a measurement of adherence to statins through a direct method using assays for selected statins in serial blood samples collected from two prospective cohorts of Danish colorectal cancer patients. Methods: We linked information on statin prescriptions from the Aarhus University Prescription Database with the cancer cohorts from Aalborg University Hospital. For statin-prescribed patients, we calculated a prescription window covering the anticipated duration of the prescription. For each statin-prescribed patient with at least one blood sample in a prescription window, we selected without replacement a never–statin-prescribed patient matched on sex, age, and calendar year of surgery. Each of the selected blood samples were analyzed using assays to detect statins. We calculated the positive and negative predictive value of the prescription registry reporting using the assay result as the gold standard. Results: We identified 73 ever–statin-prescribed patients with a total of 253 blood samples and 74 blood samples among never–statin-prescribed patients. The positive predictive value for prescribed patients, with presence of statins in at least one blood sample as the gold standard, was 93{\%} (95{\%} CI, 86{\%}-97{\%}) and the negative predictive value was 93{\%} (95{\%} CI, 86{\%}-97{\%}). Stratified results did not reveal substantial differences in predictive values. Fifty-two (71{\%}) of the statin-prescribed patients had statins in every blood sample, suggesting continuous adherence. Conclusion: This study showed a high adherence with treatment with statins among colorectal cancer patients.",
author = "Riis, {Anders H} and Rune Erichsen and Ostenfeld, {Eva B} and H{\o}jskov, {Carsten S} and Ole Thorlacius-Ussing and Stender, {Mogens Tornby} and Lash, {Timothy L} and M{\o}ller, {Holger Jon}",
year = "2019",
month = "5",
doi = "10.1002/pds.4700",
language = "English",
volume = "28",
pages = "609--615",
journal = "Pharmacoepidemiology and Drug Safety",
issn = "1053-8569",
publisher = "Wiley",
number = "5",

}

Validating registry data on statins prescriptions by blood measurements. / Riis, Anders H; Erichsen, Rune; Ostenfeld, Eva B; Højskov, Carsten S; Thorlacius-Ussing, Ole; Stender, Mogens Tornby; Lash, Timothy L; Møller, Holger Jon.

I: Pharmacoepidemiology and Drug Safety, Bind 28, Nr. 5, 05.2019, s. 609-615.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - Validating registry data on statins prescriptions by blood measurements

AU - Riis, Anders H

AU - Erichsen, Rune

AU - Ostenfeld, Eva B

AU - Højskov, Carsten S

AU - Thorlacius-Ussing, Ole

AU - Stender, Mogens Tornby

AU - Lash, Timothy L

AU - Møller, Holger Jon

PY - 2019/5

Y1 - 2019/5

N2 - Purpose: To validate prescription registry data as a measurement of adherence to statins through a direct method using assays for selected statins in serial blood samples collected from two prospective cohorts of Danish colorectal cancer patients. Methods: We linked information on statin prescriptions from the Aarhus University Prescription Database with the cancer cohorts from Aalborg University Hospital. For statin-prescribed patients, we calculated a prescription window covering the anticipated duration of the prescription. For each statin-prescribed patient with at least one blood sample in a prescription window, we selected without replacement a never–statin-prescribed patient matched on sex, age, and calendar year of surgery. Each of the selected blood samples were analyzed using assays to detect statins. We calculated the positive and negative predictive value of the prescription registry reporting using the assay result as the gold standard. Results: We identified 73 ever–statin-prescribed patients with a total of 253 blood samples and 74 blood samples among never–statin-prescribed patients. The positive predictive value for prescribed patients, with presence of statins in at least one blood sample as the gold standard, was 93% (95% CI, 86%-97%) and the negative predictive value was 93% (95% CI, 86%-97%). Stratified results did not reveal substantial differences in predictive values. Fifty-two (71%) of the statin-prescribed patients had statins in every blood sample, suggesting continuous adherence. Conclusion: This study showed a high adherence with treatment with statins among colorectal cancer patients.

AB - Purpose: To validate prescription registry data as a measurement of adherence to statins through a direct method using assays for selected statins in serial blood samples collected from two prospective cohorts of Danish colorectal cancer patients. Methods: We linked information on statin prescriptions from the Aarhus University Prescription Database with the cancer cohorts from Aalborg University Hospital. For statin-prescribed patients, we calculated a prescription window covering the anticipated duration of the prescription. For each statin-prescribed patient with at least one blood sample in a prescription window, we selected without replacement a never–statin-prescribed patient matched on sex, age, and calendar year of surgery. Each of the selected blood samples were analyzed using assays to detect statins. We calculated the positive and negative predictive value of the prescription registry reporting using the assay result as the gold standard. Results: We identified 73 ever–statin-prescribed patients with a total of 253 blood samples and 74 blood samples among never–statin-prescribed patients. The positive predictive value for prescribed patients, with presence of statins in at least one blood sample as the gold standard, was 93% (95% CI, 86%-97%) and the negative predictive value was 93% (95% CI, 86%-97%). Stratified results did not reveal substantial differences in predictive values. Fifty-two (71%) of the statin-prescribed patients had statins in every blood sample, suggesting continuous adherence. Conclusion: This study showed a high adherence with treatment with statins among colorectal cancer patients.

U2 - 10.1002/pds.4700

DO - 10.1002/pds.4700

M3 - Journal article

C2 - 30779395

VL - 28

SP - 609

EP - 615

JO - Pharmacoepidemiology and Drug Safety

JF - Pharmacoepidemiology and Drug Safety

SN - 1053-8569

IS - 5

ER -